Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:430141.
doi: 10.1155/2012/430141. Epub 2012 Oct 21.

Bortezomib-induced bronchiolitis obliterans organizing pneumonia

Affiliations

Bortezomib-induced bronchiolitis obliterans organizing pneumonia

E Vandeix et al. Case Rep Pulmonol. 2012.

Abstract

Introduction. Bortezomib is a proteasome inhibitor indicated for the treatment of multiple myeloma patients. The most frequent side effects are gastrointestinal and neurological. Serious pulmonary complications have been described rarely. Observation. This case involves a 74-year-old man suffering from IgG Kappa myeloma treated with bortezomib, melphalan, and dexamethasone. After administering chemotherapy, the patient developed an acute respiratory distress syndrome (ARDS). A surgical pulmonary biopsy proved the existence of bronchiolitis obliterans organizing pneumonia (BOOP) lesions. Systemic corticotherapy led to a rapid improvement in the patient's condition. Conclusion. This is the first reported histologically confirmed case of bortezomid-induced BOOP. Faced with severe respiratory symptoms in the absence of other etiologies, complications due to bortezomid treatment should be evoked and corticotherapy considered.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Postero anterior radiograph of the chest obtained on admission.
Figure 2
Figure 2
CT scan of the chest obtained on Day 1 showing diffuse bilateral alveolar infiltrate.
Figure 3
Figure 3
Open lung biopsy performed on day 6 (HES × 50): lesions of bronchiolitis obliterans with organizing fibroblastic polyps in alveoli.
Figure 4
Figure 4
Postero anterior radiograph of the chest on Day 12.

Similar articles

Cited by

References

    1. Miyakoshi S, Kami M, Yuji K, et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood. 2006;107(9):3492–3494. - PubMed
    1. Dun X, Yuan Z, Fu W, Zhang C, Hou J. Severe pulmonary complications after bortezomib treatment in multiple myeloma. Hematological Oncology. 2010;28(1):49–52. - PubMed
    1. Zappasodi P, Dore R, Castagnola C, et al. Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma. Journal of Clinical Oncology. 2007;25(22):3380–3381. - PubMed
    1. Kang W, Kim JS, Cho SH, Kim SK, Chang J, Park MS. Nonspecific interstitial pneumonitis after bortezomib and thalidomide treatment in a multiple myeloma patient. Yonsei Medical Journal. 2010;51(3):448–450. - PMC - PubMed
    1. Boyer JE, Batra RB, Ascensao JL, Schechter GP. Severe pulmonary complication after bortezomib treatment for multiple myeloma. Blood. 2006;108(3):p. 1113. - PubMed